SCHEMBL1339405

SCHEMBL1339405

COC(=O)c1cc(-c2ccc3c(c2)c2cc(-c4ccc(Cl)cc4Cl)c(=O)n(C)c2n3C)on1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 2/20 0.49
▸ MAPK1 P28482 1/20 0.42
▸ MAPT P10636 2/20 0.41
▸ TP53 P04637 2/20 0.41
▸ CNR1 P21554 3/20 0.39
▸ CNR2 P34972 3/20 0.39
▸ MRGPRX4 Q96LA9 1/20 0.39
▸ NPC1 O15118 4/20 0.38
▸ RAB9A P51151 4/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ THRB P10828 2/20 0.37
▸ CASP3 P42574 1/20 0.37
▸ SENP8 Q96LD8 1/20 0.37
▸ SENP7 Q9BQF6 1/20 0.37
▸ SENP6 Q9GZR1 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3267367 0.90 CDH1 (0.42) TP53CNR1CNR2NPC1RAB9A
SCHEMBL1338174 0.85 CSF1R (0.38) MAPTTP53CNR1CNR2HPGD
SCHEMBL1337166 0.83 ALPL (0.40) MAPTCNR1CNR2MEN1KMT2A
SCHEMBL1339591 0.81 MAPT (0.42) MAPTCNR1CNR2NPC1RAB9A
SCHEMBL1339131 0.81 NOTUM (0.39) NOTUMMAPTCNR1CNR2HPGD
SCHEMBL3629309 0.78 CNR1 (0.40) MAPTCNR1CNR2NPC1RAB9A
SCHEMBL1339274 0.78 KDM4E (0.40) NOTUMMAPTCNR1CNR2NPC1
SCHEMBL1336869 0.77 KDM4E (0.39) MAPTCNR1CNR2HPGD
SCHEMBL3577543 0.77 KDM4E (0.41) MAPTTP53CNR1CNR2HPGD
SCHEMBL1339427 0.77 CNR1 (0.38) MAPTCNR1CNR2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 NOTUM 3400/4885MAPK1 3718/4885MAPT 2476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback